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Parkinson disease-linked GBA 
mutation effects reversed by 
molecular chaperones in human cell 
and fly models
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Alexander J. Whitworth1,2 & Anthony H. V. Schapira3
GBA gene mutations are the greatest cause of Parkinson disease (PD). GBA encodes the lysosomal 
enzyme glucocerebrosidase (GCase) but the mechanisms by which loss of GCase contributes to PD 
remain unclear. Inhibition of autophagy and the generation of endoplasmic reticulum (ER) stress are 
both implicated. Mutant GCase can unfold in the ER and be degraded via the unfolded protein response, 
activating ER stress and reducing lysosomal GCase. Small molecule chaperones that cross the blood 
brain barrier help mutant GCase refold and traffic correctly to lysosomes are putative treatments for 
PD. We treated fibroblast cells from PD patients with heterozygous GBA mutations and Drosophila 
expressing human wild-type, N370S and L444P GBA with the molecular chaperones ambroxol and 
isofagomine. Both chaperones increased GCase levels and activity, but also GBA mRNA, in control and 
mutant GBA fibroblasts. Expression of mutated GBA in Drosophila resulted in dopaminergic neuronal 
loss, a progressive locomotor defect, abnormal aggregates in the ER and increased levels of the ER 
stress reporter Xbp1-EGFP. Treatment with both chaperones lowered ER stress and prevented the loss 
of motor function, providing proof of principle that small molecule chaperones can reverse mutant GBA-
mediated ER stress in vivo and might prove effective for treating PD.
The GBA gene encodes the lysosomal enzyme glucocerebrosidase (GCase), which cleaves the sphingolipid gluco-
sylceramide into glucose and ceramide. Homozygous mutations in the GBA gene cause Gaucher disease (GD), a 
lysosomal storage disorder1. The pathogenic features of GD are associated with the accumulation of glucosylcer-
amide in lysosomes in several cell types, including macrophages and neurons.
Although occasional reports of GD with PD appeared some years ago2,3, the link between GBA mutations and 
PD was clearly established in 20094. Both homozygous and heterozygous GBA mutations are associated with an 
approximately equal risk for the development of PD. PD patients with GBA mutations tend to have an earlier age 
of onset and greater cognitive decline4–7. GCase activity is also significantly decreased in the substantia nigra and 
anterior cingulate cortex of sporadic PD brains8–10.
Lewy bodies are α -synuclein rich neuronal protein aggregates and are a pathological hallmark of PD. 
Impairment of the autophagy-lysosomal pathway (ALP) is implicated in the abnormal accumulation of 
α -synuclein11–13. In cellular and animal models where GCase is knocked down, knocked out or which express 
pathogenic mutations, α -synuclein is found to accumulate, exhibit properties of Lewy bodies (proteinase K 
resistant; ubiquitin positive) and be co-incident with impairment of the ALP14–17. ALP inhibition has also been 
implicated with mitochondrial dysfunction observed in Gba − /− and gba − /− mice and zebrafish17,18. Zebrafish 
lacking gba also exhibit loss of dopaminergic neurons, which occurs in the absence of α -synuclein18.
However, the exact mechanism by which GCase deficiency contributes to PD pathogenesis is unclear but 
may include the accumulation of α -synuclein, impaired lysosomal function and endoplasmic reticulum (ER) 
associated stress19. Accumulation of glucosylceramide in lysosomes may contribute to lysosomal dysfunction for 
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homozygous GBA mutations but no evidence of glucosylceramide accumulation in PD brains with heterozygous 
GBA mutations has been reported20.
The two most common GBA mutations associated with PD are N370S and L444P21. These mutations have been 
reported to unfold in the ER22,23 and activate the unfolded protein response (UPR). There are three arms of the 
UPR: IRE1, PERK and ATF6. These proteins down-regulate protein translation, while enhancing the expression of 
ER chaperones, with the aim of decreasing the protein burden in the ER and refolding the proteins that have acti-
vated the UPR24. GCase that cannot be refolded by chaperones is retro-translocated to the cytoplasm and degraded 
by the ubiquitin-proteasome system25. Persistent activation of the UPR results in ER stress, with dysregulation of 
calcium and activation of apoptosis, and is implicated in several neurodegenerative disorders including PD8,12,24.
Therefore, GBA mutations in addition to impairing ALP in PD, may also elicit a gain of function by activating 
ER stress because the mutant protein is trapped in the ER. Markers of ER stress are elevated in PD brains with 
GBA mutations8 and dysregulation of ER calcium stores have been reported in cell models containing GBA muta-
tions associated with PD16,26.
Enzyme replacement therapy is an effective treatment for type I GD, but cannot cross the blood brain barrier. 
Importantly, viral expression of wild-type GBA in the brains of GD mouse models has been shown to reduce 
α -synuclein pathology, restore memory deficits and protect dopaminergic neurons15,27,28. However, this requires 
injection into the brain and does not combat the GCase trapped in the ER. A more attractive approach is the use 
of small molecule chaperones that can cross the blood brain barrier, bind to GCase, and promote proper fold-
ing and delivery to lysosomes. Two chaperones that have been found to bind GCase and improve trafficking to 
the lysosome in GD fibroblasts are ambroxol and isofagomine29–31. Previously we have reported that ambroxol 
can increase GCase activity in GD fibroblasts and fibroblasts with heterozygous GBA mutations from subjects 
with and without PD32. We have expanded our data on fibroblasts from GBA mutation carriers and investigated 
whether isofagomine has similar effects to ambroxol.
Drosophila melanogaster models of PD have proven useful for dissecting the pathogenesis of disease33, 
although Drosophila do not have a homolog of α -synuclein. We have generated fly lines expressing human wild 
type or mutant N370S and L444P GBA to assess the contribution of ER stress to disease pathogenesis in the 
absence of the well documented GCase–α -synuclein bidirectional relationship8,14,16,27. These Drosophila lines 
were also used to assess the efficacy of ambroxol and isofagomine on ER stress in vivo.
Similar to other reports, we found that expression of GBA variants induces ER stress and progressive locomo-
tor deficits34,35, as well as a modest loss of dopaminergic neurons. Feeding flies ambroxol or isofagomine alleviated 
ER stress and prevented the locomotor deficits. Hence, this model system provides evidence that GBA mutations 
cause aberrant ER stress which contributes to the pathogenic process but which can be alleviated by administra-
tion of molecular chaperones.
Results
Ambroxol and isofagomine increase GCase mRNA and enzyme activity in fibroblasts. Human 
dermal fibroblasts express barely detectable levels of α -synuclein compared to neurons (Supplementary Fig. 1). 
We therefore chose fibroblasts to investigate small molecule chaperones on mutant GBA, to be confident that 
any effects observed on ER stress were not due to the contribution of the well characterised relationship between 
perturbed α -synuclein homeostasis and mutant GCase reported in neurons and brain14–16. GCase activity was 
measured in control fibroblasts (wt/wt; CTRL), fibroblasts from PD patients with heterozygous GBA mutations 
(N370S/wt and L444P/wt) and fibroblasts from idiopathic (sporadic) PD patients (iPD). GCase activity was 
significantly decreased in N370S/wt and L444P/wt fibroblasts by 32% and 35%, respectively (P < 0.05 vs. CTRL; 
Fig. 1a). No loss of GCase activity was found in iPD fibroblasts. Similar to previous reports32,36 this decrease 
in GCase activity was concomitant with a significant decrease in both GBA mRNA and GCase protein levels 
in mutant GBA lines (P < 0.05 vs. CTRL; Fig. 1b–d). Under basal conditions, markers of UPR stress such as 
increased levels of CHOP mRNA (transcriptionally induced by both PERK and ATF6 arms of the UPR24) and 
protein levels of the chaperone BiP were significantly increased in L444P/wt by 280% (P < 0.01 vs. CTRL) and 
153% (P < 0.05 vs. CTRL), respectively (Fig. 1e,f). No markers of the UPR were significantly increased in the 
N370S/wt or iPD lines.
Treatment of control, heterozygous GBA and iPD fibroblasts with the protein chaperones ambroxol (60 μ M) 
or isofagomine (50 μ M) increased GCase activity after 6 days of treatment (Fig. 2a). These doses have previously 
been reported to be effective at increasing GCase activity over this time29,32. GCase activity was significantly 
increased in CTRL, N370S/wt, L444P/wt and iPD treated with ambroxol by 188% (P < 0.01), 206% (P < 0.05), 
199% (P < 0.01) and 174% (P < 0.01), respectively, when compared to vehicle treated cells (DMSO). Isofagomine 
increased GCase activity in CTRL, N370S/wt, L444P/wt and iPD by 161% (P < 0.01), 172% (P < 0.05), 158% 
(P < 0.05) and 166% (P < 0.05), respectively. Similarly, GCase protein expression and GBA mRNA levels were 
increased in all cell lines treated with ambroxol or isofagomine (Fig. 2b,c). Immunofluorescence of N370S/wt cells 
for GCase and the lysosomal enzyme Cathepsin D suggest that both ambroxol and isofagomine increase lysoso-
mal GCase content (Fig. 2d). A similar immunofluorescence pattern was observed for CTRL, L444P/wt and iPD 
lines treated with ambroxol or isofagomine (data not shown).
BiP levels were decreased in L444P/wt cell lines when treated with ambroxol (86 ± 12% of vehicle treated cells) or 
isofagomine (81 ± 15% of vehicle treated cells), although not significantly (Fig. 2e). Neither chaperone treatment had 
any effect on CHOP levels in L444P/wt cells (Fig. 2f). Surprisingly, 60 μ M ambroxol treatment considerably increased 
CHOP levels in CTRL cells. Titration of ambroxol indicated that 5 μ M ambroxol treatments of control, N370S/wt 
and iPD cells was enough to significantly increase GCase activity (Supplementary Fig. 2), while not increasing CHOP 
levels in CTRL cells. However, this dose was not sufficient to increase GCase activity in L444P/wt cells.
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Generation of Drosophila expressing human WT, N370S or L44P GBA. To investigate further the 
impact of GBA mutations on ER stress and the potential protective effects of ambroxol and isofagomine in vivo 
we generated transgenic Drosophila to express human wt, N370S or L444P GCase. GBA mRNA levels and protein 
expression of human GCase were similar in the wt and mutant lines (Fig. 3a,b). Despite equivalent expression lev-
els, the enzyme activity of GCase was significantly decreased (P < 0.01) by 82% in N370S flies and 75% in L444P 
flies compared to the wt line (Fig. 3c). Immunofluorescence revealed an abundant co-localisation of GCase with 
ER, however, unlike the wt, N370S and L444P caused abnormal aggregates and swellings within the ER (Fig. 3d).
Pan-neuronal expression of the GCase variants did not significantly perturb life-span (Supplementary Fig. 3) 
or cause overt degeneration of the eye even after extensive aging (Supplementary Fig. 4). However, while expres-
sion of wt GBA had no effect on motor (climbing) ability, the two mutant GBA lines showed a progressive climb-
ing defect (Fig. 4a). A significant decrease in climbing was detected after 10 days in N370S flies which deteriorated 
further by 20 days. The L444P line exhibited a significant decrease in climbing after 20 days. Furthermore, the 
number of dopaminergic neurons in both N370S and L444P flies after 30 days was significantly decreased com-
pared to wt GBA flies (Fig. 4b).
To investigate the possible induction of ER stress we used a ER stress reporter transgene, Xbp1-EGFP, where 
GFP is only expressed following an ER stress-induced splice event37. Using the developing eye tissue as a tractable 
system, as previously reported34 expression of wt GBA resulted in increased Xbp1-EGFP levels compared to con-
trol (Fig. 5). However, expression of both N370S and L444P GBA induced significantly higher Xbp1-EGFP levels, 
relative to wt GBA flies (Fig. 5), indicating these forms caused an increased level of ER stress.
Ambroxol and isofagomine reduce ER stress and reverse locomotor deficits in Drosophila with 
mutant GBA. GBA expressing flies were next raised on food containing ambroxol (500 μ M) or isofagomine 
(50 μ M). Isofagomine has been reported to bind more potently to GCase than ambroxol29,38,39. Therefore to reduce 
the chance of toxic side effects we used a lower dose of isofagomine. Exposure to either chaperone during devel-
opment significantly reduced the levels of Xbp1-EGFP compared to untreated flies (Fig. 6a,b). Notably, treatment 
with isofagomine was able to reduce the high Xbp1-EGFP levels induced by all GBA variants back to levels com-
parable to control flies. Thus, these treatments were able to reverse the elevated ER stress in vivo.
To determine whether the reduction of ER stress by these chaperones provided a functional benefit to the flies, 
we assessed the locomotor ability of GBA expressing flies fed with ambroxol or isofagomine for 10 days. Strikingly, 
both chaperones were able to completely prevent the age-dependent decline in climbing ability caused by the 
expression of mutant GBA (Fig. 6c).
Figure 1. Expression and activity of GCase decreased in fibroblasts from Parkinson patients with 
heterozygous GBA mutations. (a) Analysis of GCase activity (n = 5 different cell lines/group) in fibroblasts 
from control subjects (wt/wt; CTRL), Parkinson subjects with N370S/wt, L444P/wt GBA mutations or 
idiopathic PD (wt/wt; iPD). (b) qRT-PCR analysis of GBA mRNA levels in indicated fibroblasts (n = 3 cell 
lines/group). (c) Immunoblot of fibroblasts for GCase protein expression. Protein loading normalized against 
β -actin. (d) Densitometric analysis of immunoblots (n = 5 cell lines/group). (e) qRT-PCR analysis of CHOP 
mRNA in fibroblasts (n = 7). (f) Immunoblot analysis of BiP protein levels in fibroblasts (n = 6). Protein loading 
normalised against β -actin. Data expressed as % CTRL fibroblasts. Quantitative data indicate means ± S.E.M. 
from indicated biological replicates. One-way ANOVA with Bonferroni’s correction was applied across the 
different groups (*P < 0.05, **P < 0.01 versus CTRL).
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Isofagomine but not ambroxol significantly increased GCase activity by 170 ± 11% in wt flies (P < 0.05 versus 
vehicle treated wt flies) and 194 ± 7% in L444P flies (P < 0.05 versus vehicle treated L444P flies; Fig. 7a). The 
increased GCase activity following isofagomine treatment in wt and L444P flies was concomitant with an increase 
in protein levels (Fig. 7b). Treatment of human cell lysates with endoglycosidase H has been used to identify 
GCase species trapped in the ER22,23. Treatment of fly lysates with endoglycosidase H yielded the same pattern in 
wt and mutant GBA lines and was unaffected by chaperone treatment (Fig. 7b).
Discussion
In this study we have used human cell lines and Drosophila models to investigate the biochemical consequences of 
the N370S and L444P GBA mutations that cause GD and significantly increase the risk for PD, and to evaluate the 
effects of two chaperones to reverse the abnormalities induced by these mutations. Our results confirm that the 
mutations cause reductions in GCase activity and elevated ER stress in the L444P fibroblasts and both the N370S 
and L444P flies. The flies exhibited reduced climbing activity and a loss of tyrosine hydroxylase positive neurons. 
Effects were partially reversed in flies by ambroxol and isofagomine.
Similar to other studies, we find that treatment of human dermal fibroblasts for several days with ambroxol or 
isofagomine increases GCase activity, protein expression and co-localisation with lysosomes29,30,32,36,40. Furthermore, 
this increase in GCase activity and protein expression occurs in control fibroblasts and fibroblasts from idiopathic 
PD to a similar extent as fibroblasts from PD patients with heterozygous GBA mutations or GD fibroblasts32,36. 
Both ambroxol and isofagomine treatment of fibroblasts increased GBA mRNA levels suggesting that these com-
pounds elicit cellular responses to promote GCase expression in addition to their chaperoning ability. We opted to 
investigate treatment of cells with ambroxol or isofagomine over several days as we anticipate that this is the period 
of time required to re-fold GCase and for increased GCase trafficking to lysosomes to elicit measurable improve-
ments in lysosomal function. Macrophages derived from inducible pluripotent stem cells (iPSC) from GD patients 
required five days of ambroxol or isofagomine treatment to reduce production of proinflammatory cytokines and 
improve the clearance of phagocytosed red blood cells41. Furthermore, ALP inhibition and perturbed α -synuclein 
Figure 2. Ambroxol and isofagomine treatment increase GCase activity, protein levels and GBA mRNA 
in fibroblasts. (a) GCase activity in fibroblasts following 6 day treatment with vehicle (veh, black), 60 μ M 
ambroxol (ABX, grey) or 50 μ M isofagomine (IFG, white). Data are expressed as % GCase activity compared to 
respective vehicle treated cell line (n = 3). (b) Immunoblot for GCase protein expression following treatment 
with vehicle, ABX or IFG. Protein loading normalized against β -actin. (c) qRT-PCR analysis of GBA mRNA 
levels in fibroblasts treated with veh, ABX or IFG. Data normalized against β-actin mRNA and data expressed 
as % of vehicle treatment for respective cell line (n = 3). (d) Immunofluorescence for GCase (red) and the 
lysosomal marker cathepsin D (CatD, green) in N370S/wt fibroblasts treated with vehicle, ABX or IFG. Nuclei 
were counterstained with DAPI (blue). Scale bar 3 μ m. (e) Immunoblot for BiP protein levels in fibroblasts 
treated with vehicle (V), ambroxol (A) or isofagomine (I). Protein loading normalized against β -actin and data 
expressed as % of vehicle treatment for respective cell line (n = 4). (f) qRT-PCR analysis of CHOP mRNA levels 
in fibroblasts treated with veh, ABX or IFG. Data normalized against β -actin mRNA levels and data expressed as 
% of vehicle treatment for respective cell line (n = 3). Quantitative data indicate means ± S.E.M. from indicated 
biological replicates. One-way ANOVA with Bonferroni’s correction was applied across the different groups 
(*P < 0.05, **P < 0.01 versus vehicle treatment of respective cell line).
www.nature.com/scientificreports/
5Scientific RepoRts | 6:31380 | DOI: 10.1038/srep31380
homeostasis observed in dopaminergic neurons derived from iPSC from PD patients with GBA mutations16,42 
require several days of small molecule chaperone treatment to be reversed (Yang et al., manuscript submitted).
Ambroxol treatment has been shown in fibroblasts to induce the coordinated lysosomal expression and reg-
ulation (CLEAR) network mediated via transcription factor EB32. Activation of the CLEAR network increases 
lysosomal biogenesis, clearance of damaged proteins and organelles by macroautophagy and maintains mito-
chondrial homeostasis43–46. In addition to increased GCase activity and expression levels, ambroxol treatment 
has been reported to increase the expression/activity of lysosomal cathepsins, the GCase transporter LIMP2, and 
saposin C, the endogenous activator of lysosomal GCase activity32,36. Recently, ambroxol has been reported to 
affect calcium homeostasis in lung type II pneumocytes47, which if applicable to other cell types, would modulate 
many cellular pathways.
Further studies on different ambroxol concentrations and duration of treatment are needed to dissect the 
physiological actions of this chaperone. The beneficial effects of ambroxol on GCase activity, lysosomal locali-
sation, and inflammatory mediators have typically used concentrations of 50–100 μ M30,32,36,41. The Km and Ki of 
GCase for ambroxol at pH 7.0 has been reported to be about 5–10 μ M30,38, while the current therapeutic doses 
Figure 3. Expression of GBA variants co-localize with the endoplasmic reticulum. (a) qRT-PCR analysis of 
GBA mRNA levels in transgenic fly heads expressing GBA variants via elav-GAL4. (b) Immunoblot analysis of GBA 
protein levels in fly heads. (c) Analysis of GCase activity in heads of the indicated genotypes. (d) Immunostaining 
of anti-GCase (red) in salivary glands co-localizes with the ER marker KDEL-GFP (native GFP; green). DNA is 
marked with Hoechst (blue). Arrowheads indicated abnormal ER swelling. Scale bar 50 μ m. Control genotypes 
are GAL4/+ . Quantitative data indicate means ± S.E.M. from 3–4 biological replicates. One-way ANOVA with 
Bonferroni’s correction was applied across the different genotypes (**P < 0.01 vs. GBA wt; ns, non-significant).
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of ambroxol (90–120 mg/day) yield a plasma drug concentration of 0.6–1.2 μ M47. We found that 5 μ M ambroxol 
significantly increased GCase activity in control, N370S/wt and iPD fibroblasts, and was not accompanied by 
increased CHOP mRNA levels seen in control fibroblasts at the higher dose. Unlike 100 μ M ambroxol, 1 μ M 
does not mobilise calcium47. However, higher doses may be required for the L444P GCase mutation as 5 μ M 
was ineffective at increasing GCase activity, and has previously been shown to require higher doses (50 μ M) to 
increase GCase activity by 30% and reduce ER trapping in L444P/L444P GD fibroblasts31. It is apparent from this 
and other studies that further characterization of the effects of ambroxol and isofagomine on ER stress makers in 
human models for the common GBA mutations is required.
Transgenic expression of human GBA in Drosophila generated substantial GCase activity, compared to back-
ground endogenous levels. However, the expression of N370S and L444P GCase resulted in significantly less 
GCase activity, increased ER stress, progressive loss of locomotor ability and the loss of dopaminergic neurons. 
Figure 4. Analysis of neurodegeneration phenotypes upon GBA expression. Expression of GBA variants 
was induced by elav-GAL4, and flies were analyzed for (a) climbing ability and (b) dopaminergic neuron 
immunostaining with ageing. Statistical analysis of climbing assays used Kruskal-Wallis with Dunn’s multiple 
comparisons test, whereas one-way ANOVA with Bonferroni’s correction was used to analyze neuron loss 
(*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, non-significant). Data represent mean ± SEM.
Figure 5. Expression of GBA variants increase ER stress. (a) Analysis of ER stress induction in eye imaginal 
discs expressing GBA variants via GMR-GAL4. Induction of ER stress was monitored by the ER stress reporter 
Xbp1-EGFP (green). GBA expression is indicated by anti-GBA immunostaining (red). DNA is marked with 
Hoechst (blue). (b) Quantification of Xbp1-EGFP levels compare to control (GMR-GAL4/Xbp1-EGFP). Scale 
bar 100 μ m. Data represents means values from at least 10 imaginal discs. Statistical analysis was calculated 
using one-way ANOVA with Bonferroni’s correction (*P < 0.05, ****P < 0.0001). Data represent mean ± SEM.
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Figure 6. Ambroxol and isofagomine treatment reduce ER stress and rescue climbing deficits. (a) Analysis 
of ER stress induction in eye imaginal discs expressing GBA variants via GMR-GAL4 in the presence or absence 
of ambroxol (500 μ M) or isofagomine (50 μ M) for 4 days. Induction of ER stress was monitored by the ER 
stress reporter Xbp1-EGFP (green). Scale bar 100 μ m. (b) Quantification of Xbp1-EGFP levels in the indicated 
conditions. Data represents mean ± SEM from at least 10 imaginal discs. Statistical analysis was calculated 
using one-way ANOVA with Bonferroni’s correction. (c) Analysis of adult climbing ability in flies expressing 
GBA variants via elav-GAL4 in the presence or absence of ambroxol (500 μ M) or isofagomine (50 μ M) for 
10 days. Kruskal-Wallis with Dunn’s multiple comparisons test was used for analysis (*P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001; ns, non-significant). Data represent mean ± SEM.
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Importantly, since Drosophila do not express endogenous α -synuclein, these findings show that mutant GCase 
mediated-ER stress is capable of causing loss of dopaminergic neurons in the absence of α -synuclein toxicity. 
Human and mouse models of pathogenic GCase have previously shown phenotypes relevant to PD, but because 
of the concomitant inhibition of the ALP and subsequent accumulation of α -synuclein, it was not possible to dif-
ferentiate between the deleterious contribution of ER stress and autophagy impairment14–16,42. ER stress has been 
observed in other Drosophila models expressing human pathogenic mutant GCase, such as N370S, L444P and 
R120W, RecNcil34,35. During preparation of this manuscript ambroxol has also been shown to partially reverse the 
ER stress and loss of dopaminergic neurons in Drosophila expressing N370S and L444P GBA48. We have extended 
these observations by showing that isofagomine, as well as ambroxol34, can reverse the ER stress, and importantly, 
that both these chaperones can rescue locomotor deficits. Recently, deletion of the GBA homolog dGBA1b in 
Drosophila has been shown to affect locomotor ability and decrease lifespan49. Ubiquitin deposits and accumula-
tion of Ref(2)P, the Drosophila homolog of p62/SQSTM1, also occurred, suggestive of impaired autophagy/quality 
control mechanisms. However, no change in dopaminergic neuronal number was observed, although evidence of 
other neurodegeneration was detected49.
The mechanism by which ambroxol and isofagomine exert these effects is not clear. We did observe a signifi-
cant increase in GCase activity in the wt and L444P fly models following isofagomine treatment, while ambroxol 
had no significant effect on either wt or mutant GCase. It appears increasingly likely that these compounds may 
have multiple effects that may include the chaperoning of mutant GCase trapped in the ER, reversal of ER stress 
and transcriptional activation. The latter property may be most clearly reflected in our human-derived cell model 
where increases in GBA mRNA, protein levels and activity are seen even in the presence of only wt alleles. The 
N370S GBA mutant fly model response to treatment without a significant increase in GCase activity may in 
turn reflect effects on the reversal of ER stress and as yet unidentified additional mechanisms. In this respect it 
is notable that isofagomine was found to be protective in a neuronopathic GD mouse model by preventing the 
dysregulation of several mRNA and miRNA species in the brain involved in several pathways including neu-
roinflammation, mitochondrial function and axon guidance50. This protection occurred despite isofagomine not 
reducing the accumulation of substrate.
Regardless of the mechanism, reversal of ER stress and full restoration of locomotor function in our fly mod-
els by small molecule chaperones is an important proof of principal. Data suggest that the wild-type GCase 
becomes trapped in the ER and trafficking to lysosomes becomes impaired when cellular α -synuclein levels are 
elevated8,9,14. It is envisaged that if wild-type/mutant GCase can be refolded in the ER of humans, reducing ER 
stress and improving the trafficking of GCase to lysosomes, this will have important benefits not only for neu-
ronopathic forms of GD (Type 2 and Type 3), for which no therapy is currently licensed, and PD patients with 
GBA mutations, but also sporadic forms of PD. Increased lysosomal GCase will help to reduce the accumulation 
of substrate in type 2 and type 3 GD, while in PD this should improve autophagy, thus reducing the formation of 
pathogenic α -synuclein species with a beneficial effect on disease pathogenesis51.
Materials and Methods
Fibroblast tissue culture lines. Human dermal fibroblasts were generated from skin biopsies taken 
from five controls (wt/wt), five PD patients with N370S/wt GBA mutations, five PD patients with L444P/wt 
GBA mutations and five patients with idiopathic PD. Controls were age-matched to PD patients and mutations 
were confirmed by Sanger sequencing. Fibroblasts were cultured in Dulbecco’s modified Eagle media (4.5 g/L 
glucose) supplemented with 10% (v/v) fetal calf serum, 1 mM sodium pyruvate and penicillin-streptomycin. 
Fibroblasts were not used after passage 12. All biopsies were obtained following informed patient consent fol-
lowing Hampstead Research Ethical committee approval (10/H0720/21/21). The methods were carried out in 
accordance with the relevant guidelines in the above-mentioned ethics approval.
Chaperone treatment of fibroblasts. Treatment of fibroblasts with ambroxol (5–60 μ M; Sigma-Aldrich 
A9797) or isofagomine (D-tartate (50 μ M; Cayman Chemical 16137) started when cells were 50% confluent in 
Figure 7. GCase activity and protein levels in wt, N370S and L444P flies following chaperone treatment. 
(a) GCase activity measured in flies treated with vehicle (veh, black), ambroxol (ABX, grey) or isofagomine 
(IFG, white) for 10 days. Data are expressed as % GCase activity compared to respective veh treated fly line. 
(b) Representative immunoblot for human GCase in respective fly lines in the absence or presence of ABX and 
IFG for 10 days. Lysates were treated with or without endoglycosidase H (endoH) prior to immunoblot. Data 
represent mean ± SEM (* P < 0.05 vs. respective vehicle treatment).
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10 cm plates. Fibroblasts were treated with vehicle (dimethyl sulfoxide) or respective chaperone on days 0, 2, and 
4. Fibroblasts were harvested on day 6 by trypsinisation and washed once in phosphate buffered saline (PBS) prior 
to freezing.
Measurement of GCase activity. GCase activity was measured in fibroblast cell lysates (~20 μ g protein) 
in McIlvaine citrate-phosphate buffer (pH 5.4) with 10 mM sodium taurochlorate and 5 mM 4–methylumbellif-
eryl–β –D–glucopyranoside as substrate at 37 °C as previously described8. The reaction was stopped with 0.25 M 
glycine (pH 10.4) and 4–methylumbelliferone fluorescence measured on a plate reader (excitation, 360 nm; emis-
sion 460 nm). Data were expressed as nmol 4–methylumbelliferone/h/mg protein.
Drosophila (~20) were homogenised in 200 μ l RIPA buffer (150 mM NaCl, 1% (v/v) NP-40, 1% (w/v) sodium 
deoxycholate, 0.1% (w/v) SDS, 50 mM Tris, pH 8). Debris was pelleted and homogenate diluted in H2O to have a 
2 mg/ml protein concentration. An aliquot (20 μ g protein) was assayed as above. GCase activity was completely 
abolished in the presence of the GCase inhibitor conduritol B epoxide (10 mM). Note that GCase activity meas-
ured in RIPA buffer yields similar results as lysates prepared in 1% (v/v) TX-100 in PBS.
Immunoblotting. Fibroblasts were lysed in 1% (v/v) Triton X-100 in PBS supplemented with protease inhib-
itors. For Drosophila samples, immunoblotting was done following standard protocols as described previously52. 
Proteins samples were isolated from whole adult fly heads. Protein lysates (20 μ g) were resolved by SDS-PAGE 
and transferred to Hybond P (GE Healthcare). Blots were probed with antibodies against human GCase (clone 
2E2, 1:1000, Merck Millipore), BiP (abcam, ab21685) or β -actin (human: abcam, ab82618; Drosophila: clone 
C4, 1:10000, Merck Millipore). Bands were detected with respective horse radish peroxidase-linked secondary 
antibodies (Dako) and Luminata Forte enhanced chemiluminescence (Merck Millipore). Density of bands was 
determined using Image Lab software 5.1 (Bio-Rad).
Endoglycosidase H treatment of fly lysates. Fly lysates were prepared as for immunoblotting and 20 μ g 
protein treated with 1000 units of endoglycosidase H (New England Biolabs) according to manufacturer’s instruc-
tions for 2 hours at 37 °C. Reaction was stopped by addition of gel loading dye and lysates immunoblotted for 
human GCase as above.
Quantitative real time PCR. For cell samples, RNA was extracted from fibroblasts using RNeasy mini kit 
(Qiagen) and converted to cDNA (QuantiTect, Qiagen or nanoscript, Primer Design) and relative mRNA levels 
for GBA and β-actin were measured using TaqMan assays (GBA, Hs00986836_g1; β-actin, Hs99999903_m1; 
Applied Biosystems) using a STEP One PCR machine (Applied Biosystems). CHOP mRNA levels were measured 
using QuantiTect SYBRgreen (Qiagen) using the following primers: CHOP, ACC AAG GGA GAA CCA GGA 
AAC G, TCA CCA TTC GGT CAA TCA GAG C; β-actin, TCT ACA ATG AGC TGC GTG TG, GGT GAG 
GAT CTT CAT GAG GT. Relative GBA and CHOP mRNA levels were calculated using the 2−ΔΔCT method and 
normalised against β-actin.
For Drosophila samples, RNA was extracted using a RNeasy RNA purification kit (Qiagen), and cDNA 
was synthesized using a Protoscript II first-strand cDNA synthesis kit (New England BioLabs) according 
to the manufacturers’ instructions. Relative GBA mRNA levels were calculated using the 2−ΔΔCTmethod 
and normalized to the ribosomal reference gene, RNA18S. The primers used for Drosophila qRT-PCR 
were as follows: GBA : TGGGCAGTGACAGCTGAA, CTGGAAGGGGTATCCACTCA; RNA18S: 
TCTAGCAATATGAGATTGAGCAATAAG, AATACACGTTGATACTTTCATTGTAGC.
Immunofluorescence. Fibroblasts were treated as above with chaperones. Cells were fixed with 3.7% par-
aformaldehyde (PFA), permeabilised with methanol and then 0.3% (v/v) Triton X-100 in phosphate buffered 
saline, and blocked in BlockAce (BioRad). Permeablised cells were incubated overnight (4 °C) with anti-GCase 
antibody (clone 2E2, 1:100, Merck Millipore) and anti-cathepsin D antibody (clone EPR3057Y, 1:100, abcam). 
Respective fluorescent secondary antibodies (alexa fluor-488/594, 1:100, Invitrogen) were used for detection and 
coverslips mounted in CitiFluor containing DAPI.
Salivary glands and eye imaginal discs were dissected from third instar larvae and fixed with 4% PFA/
PBS solution for 20 min at room temperature, then permeabilised using 0.1% Triton X-100/PBS solution for 
3 × 10 min. Samples were blocked for 1 h in 1% bovine serum albumin/PBS solution before addition of the pri-
mary antibody for 2 h. Antibodies used were: mouse anti-hGBA (clone 2E2, 1:100, Merck Millipore). AlexaFluor 
488 and 568 secondary antibodies from Invitrogen (1:200) were added in 1% PBS for 2 h, then cell nuclei were 
stained with 0.1 μ g/ml Hoechst for 5 min. UAS-KDEL-EGFP and UAS-Xbp1-EGFP were imaged using the native 
GFP. Fluorescence quantification was performed using ImageJ using the analyze particles function and measuring 
the area.
Drosophila brains were dissected from 30-day old flies and immunostained with anti-tyrosine hydroxylase 
(Immunostar Inc. 22491, 1:100) as described previously53. Brains were imaged with an Olympus FV1000 confocal 
with SIM-scanner on a BX61 upright microscope using a 63X oil 0.95 NA objective. Tyrosine hydroxylase-positive 
neurons were counted under blinded conditions.
Drosophila stocks and procedures. Drosophila were raised under standard conditions at 25 °C 
(unless otherwise indicated) on agar, cornmeal and yeast food. w1118, elav-GAL4, GMR-GAL4, fkh-GAL4, 
UAS-KDEL-GFP, and UAS-Xbp1-EGFP strains were obtained from the Bloomington Drosophila Stock Center 
(Bloomington, IN). Transgenic lines expressing human GBA (UAS-hGBA) were constructed by cloning the entire 
open reading frame (WT, N370S and L444P) into pUAST-attB vector (BestGene Inc.). The ZH-51C attP site 
was used for phiC31 site-directed integration (Bloomington stock, 24482). For all integration events, multiple 
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independent lines were initially isolated and assessed for consistent effects before selecting single lines for further 
analysis. Climbing assays were performed as previously described54. For all the experiments only males were used.
Chaperone treatment of flies. For chaperone feeding, flies of the specified genotypes were maintained 
on standard media containing ambroxol hydrochloride (Sigma-Aldrich A9797) or isofagomine (D-tartrate) 
(Cayman Chemical 16137), dissolved in water, to final concentrations of 500 μ M and 50 μ M. For eye imaginal 
discs analysis, third instar larvae were raised in food containing drug (4 days feeding during larval stages), and 
imaginal discs were analyzed by immunohistochemistry and quantified using Image J. At least 10 discs were ana-
lyzed per genotype. For climbing assays at least 50 adult males collected from crosses raised on standard media 
were aged on food containing drug for 10 days before analyzing behavior.
Life span. At least 100 recently emerged adult males were collected under light anesthesia and housed at a 
density of 25 males per vial. Flies were passaged every other day, and the number of dead flies was recorded.
Light microscopy imaging. Light microscopy imaging was assessed using a Nikon motorized SMZ stereo 
zoom microscope fitted with 1x Apo lens. Extended focus images were then generated using Nikon Elements 
software, using the same settings for all the genotypes. Flies were anaesthetised during the process. All animals 
of a given genotype displayed essentially identical phenotypes and randomly selected representative images are 
shown.
Statistical analysis. Calculations were performed using GraphPad Prism 6.0. Adult climbing analysis 
is not normally distributed so the data were analyzed using Kruskal-Wallis non-parametric test with Dunn’s 
correction for multiple comparisons. Protein and mRNA expression levels in fibroblasts and Drosophila, and 
dopaminergic neurons count significance was determined by one-way analysis of variance (ANOVA) with the 
Bonferroni’s multiple comparison test. For life span experiments Log-rank (Mantel-Cox) test was used for the 
analysis. Significance levels are indicated in figure legends. Unless specifically indicated, no significant difference 
was found between a sample and any of the other samples.
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